STZ
58
3
PSX
47
3
SYF
93
-2
STX
52
-4
PM
58
2
LOW
58
2
DOW
30
2
REGN
42
-2
JCI
61
-2
MU
32
-6
AVY
53
2
SLG
62
-4
UHS
54
-4
GLW
48
-5
EFX
41
-2
WDC
38
-3
GOOG
69
-10
BK
72
-2
LRCX
46
-2
CAH
60
2
STZ
58
3
PSX
47
3
SYF
93
-2
STX
52
-4
PM
58
2
LOW
58
2
DOW
30
2
REGN
42
-2
JCI
61
-2
MU
32
-6
AVY
53
2
SLG
62
-4
UHS
54
-4
GLW
48
-5
EFX
41
-2
WDC
38
-3
GOOG
69
-10
BK
72
-2
LRCX
46
-2
CAH
60
2
Financhill
Back

Capricor Therapeutics 10K Form

Buy
59

CAPR
Capricor Therapeutics

Last Price:
18.47
Seasonality Move:
15.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CAPR News And Ratings

See the #1 stock for the next 7 days that we like better than CAPR

CAPR Financial Statistics

Sales & Book Value

Annual Sales: $25.18M
Cash Flow: $-12.37M
Price / Cash Flow: 0
Annual Sales: $0.36
Price / Book: 51.2

Profitability

EPS (TTM): -0.89000
Net Income (TTM): $-27.95M
Gross Margin: $500K
Return on Equity: -261.27%
Return on Assets: -60.85%

Capricor Therapeutics Earnings Forecast

Key Capricor Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 6 years for CAPR is 100.00%.
  • The Selling, General & Administrative Expenses for CAPR have been equal to 49.11% of Gross Profit Margin.
  • The Research & Development expenses have been 144.76% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CAPR is -88.52% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 12 years.

Capricor Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CAPR
CUSIP: 14070B
Website: capricor.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.37
Quick Ratio: 1.33

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CAPR Technical Analysis vs Fundamental Analysis

Buy
59
Capricor Therapeutics (CAPR) is a Buy

Is Capricor Therapeutics a Buy or a Sell?